|
.. , .. , ..
,
(
1999)
,
1 2.
90%
,
2.
,
().
DCCT (1993)
UKPDS (1998). ,
,
( 10 )
1
76%,
54%,
60%,
39%
54%.
2, ,
, , .
, ,
16%. , ,
,
,
,
(
,
.),
,
.
2
,
..
,
,
.
,
,
.
1.
,
2
.
1998.
2 ,
2.
2
.
,
,
(.
3).
, ,
,
.
, ..
(
)
,
.
2
,
,
,
,
.
2
:
,
(
); ();
,
,
2
, ,
,
3
();
,
. ,
(
2
),
(
+
,
2 ).
,
2 ,
4.
,
2 .
5.
,
.
,
(R.K. Campbell, 1998).
.
b
.
,
b,
ʖԖ,
(ʖԖ ),
/ , ,
, .
,
,
2+
,
.
,
/
II ( Mshlig et al,. 1997, AguilarBryan
1999).
,
,
(4 4),
[
140icDa (SUR1)]
KIR6.2.
SUR1
KIR6 2,
,
.
2
SUR1. SUR1,
,
KIR6.2,
. ,
,
. ,
(R.A. DeFionzo, 1999). ,
in vitro
,
(L.C.
Groop, 1992)
,
,
.
,
.
, ,
, ,
,
.
2
.
, 23
,
.
,
,
. ,
, ,
2 3
,
.
.
,
.
2 3
. , ,
, ,
,
.
,
,
,
,
yc
2
(
).
,
,
,
,
,
2 .
, 100%
,
,
,
. ,
(
),
.
,
.
90
2
()
.
,
(
)
(14 ).
,
.
,
,
,
b.
,
,
.
,
,
,
,
b,
.
,
,
.
,
1
[ ..
140000 (SUR 1)]
KIR6.2.
, SUR 1,
1115.1
(),
17
(),
NBF 1
NBF 2,
Mg2+A/AT
(. Ueda et al.,1999).
SUR 1 KIR6.2,
.
KIR6.2 SUR 1,
.. 1115.1 .
,
,
,
(KIR6x),
.
: SUR 1
SUR 2
SUR 3
.
. , b
SUR
1/KIR6.2; SUR 2A/KIR6.2
SUR 2B/KIR6.1 ( KIR6.2). E. Brekardm et al. (1999)
,
(,
, )
(SUR
1/KIR6.2 SUR 2B/KIR6.2) 36 ,
.
,
(SUR/KIR6x)4.
,
,
. ,
15 ,
1217 ,
(I. Uhde et al., 1999).
A.P. Babenko et al. (1999),
,
NBF 1 2 SUR 1 1217
15. , ,
216.2,
15
SUR 1,
.
KIR6.2.
,
SUR 1
SUR 1 KIR6.2,
KIR6.2
.
in vitro
.
KIR6.2
(Thomas
P.M. et al., 1996).
(Thomas P. et al., 1995).
,
2
SUR 1 (Hani
E.. et al., 1997) KIR6.2 (Hani E.H.
et al., 1998).
,
,
,
2 ,
2
,
.
, ,
,
.
KIR6.2
SUR 1
KIR6.2,
. NBF 1
Mg2+ NBF 2 SUR 1
.
,
()
,
.
,
2,23
, 810
, (G.
Muller et al., 1994).
,
23 ,
. ,
,
. 140 ,
,
.. 65 ,
, SUR X.
, ,
140 ,
.. 40 65 (Aschcroft F.M.,
Gribble F.M., 1999),
,
SUR X,
, .
,
:
SUR 1,
SUR X.
KIR6.2
, ,
b
.
in vivo
(,
, ),
(A. Vegh, J.G. , 1996), ,
, 25
.
, ,
,
.
(. Geisen
., 1996).
2 /
,
.
20
/ 4
,
.
,
,
1/5 .
,
,
,
,
,
,
,
,
ST.
,
.
2
()
.
, G. Muller,
.
in vitro in vivo
, ,
36
,
,
90 /
; 180
/
;
90 / 1,8
/
.
.
(
)
: 0,03;
0,07; 0,11
0,16.
:
0,6 /,
1,3; 1,6
3,3 / (G. Muller, 2000).
.
,
(1 4 164
148% ),
(J. Eckel).
,
,
.
,
4
1,
.
,
J.E. Pessin et al. (1999) .,
4 33,5
, 78 . ,
4,
(3)
().
, ,
4550%
.
3
3540%
.
.
,
.
,
6.
,
,
.
,
,
.
.
..290,
( .)
,
(,
, ,
.).
. ,
,
.
,
0,15 /,
1,5 /
,
0,45 /
(D.W. Landry et al.,
1992)
(2 //),
(25 //)
(500 //)
1
,
,
.
.
,
,
.
(G. BallangiPordmy et al.,
1992). ,
,
,
.
.
40
2,
,
, 12,
.
, 12
(Y. Ozaki et al., 1992).
2
30
,
,
.
,
,
,
, ,
.
, ,
, ,
,
, b
. ,
, ,
,
, ,
, , ,
,
,
.
.
123 4 .
(12 )
710 .
6
. ,
() ,
2 (
).
(
,
..).
1
,
,
.
,
2
(
, ,
,
).
,
,
(
).
.
(
,
)
.
2
,
.
,
.
2
, ,
.
(),
,
.
:
1.
Campbell R Glimepiride role of new sulfonylureas in the
treatment of type 2 diabetes mellitus, Ann Pharmacother, 1998,
32. 10441052
2.
DeFronzo R A , Pharmacologic therapy for type 2 diabetes
mellitus, Ann Intern Med, 1999, 131, 281303
3.
Diabetes Control and Complications Trial Research Group The
effect of intensive treatment of diabetes on the development and
progression of longterm complications in insulindependent
diabetes mellitus, N Engi J Med, 1999, 329, 977986
4.
UK Prospective Diabetes Study Group/ Intensive bloodglucose
control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients
with type 2 diabetes. Lancet, 1998, 352, 837853
5.
Geisen , Vegh A, Krause E , Papp J G, Cardiovascular effects
of conventional sulfonylureas and glimepinde, Horm Metab Res,
1996, 28, 496507
6.
Mshlig M, Wolter S, Mayer P et al, Insulinoma cell contain an
isoform of Ca2+/calmodulmdependent protein kinase 115
associated with insulin secretion vesicles, Endocrinology, 1977,
138, 25772584
7.
Eckel J, Direct effects of glimepinde on protein expression of
cardiac glucose transporters, Horm Metab Res, 1996, 28, 508511
8.
AguilarBryan L, Bryan J, Molecular biology of adenosine
tnphosphatesensitrve potassium channels, Endocr Rev 1999, 20,
101135
9.
Brecardm E, Dorschner H, Schwanstecher et al, Stoichiometry
of sulfonylurea action, Diabetologia, 1999, 42, supp 1. N 232,p
A65
10.
Ueda , Komine J, Matsuo M. et al, Cooperative binding of ATP
and MgADP in sulfonylurea receptor is modulated by glibenclamide,
Proc Nail Acad Sci USA, 1999, 96, 12681272
11.
Uhde I, Toman A, Gross, Schwanstecher C, Identification of the
potassium channel opener site on sulfonylurea receptors, J Biol
Chem, 1999, 274, 2807928082
12.
Babenko A.H., Gonzalez G, Bryan J , The tolbutamide site of SUR1
and a mechanism for its functional coupling to Kaip channel
closure, FEBS Lett, 1999, 459, 367376
13.
Thomas P, Ye Y, Lightner E, Mutations of the pancreatic islet
inward rectifier KIR6 2 also lead to familial persistent
hypennsulinemic hypoglycemia of infancy, Hum Mol Genet, 1996,
5,18091812
14.
Thomas P M, Cote G J, Wohlik N et al, Mutations in sulfonylyrea
receptor gene in familial persistent hypennsulinemic
hypoglycemia of infancy, Science, 1995, 268, 426429
15.
ni E H. Clement , Velho G et al, Genetic studies of the
sulfonylurea receptor gene locus in NIDDM and in morbid obesity
among French Caucasians, Diabetes, 1997, 46, 688694
16.
ni E H, Boutin P, Durand E et al, Missense mutations in the
pancreatic islet beta cell inwardly rectifying K+
channel gene (KIR6 2/BIR) a metaanalysis suggests a role in the
polygemc basis of type II diabetes mellitus in Caucasians,
Diabetologia, 1998, 41, 15111515
17.
Muller G, Hartz D, Punter J et al, Differential interaction of
glimepinde and glibenclamide with the (3cell sulfonylurea
receptor I Binding characteristics, Biochim Biophys Acta, 1994,
1191,267277
18.
Ashcroft F M, Gnbble F M, ATPsensitive K+ channels
and insulin secretion their role in health and disease,
Diabetologia, 1999. 42, 903919
19.
Muller G, The mollecular mechanism of the msulmmimetic/sensitizing
activity of the an+irliahptif ォiiilfnnvliirea
drue amarvl Mol Med, 2000, , 907933
20.
Pessin J E, Thurmond D C, Elmendorf et al, Molecular basis of
insulinstimulated GLUT4 vesicle trafficking, J Biol Chem, 1999,
274, 25932596
21.
Andry D W et al, The ATPsensitive K+channel mediates
hypotension in endotoxemia and hypotoxic lactat acidosis in dog,
J Clin Invext, 1992, 89, 20712074
22.
BallangiPordiny G et al, Effect of glimepiride on electrical
activity of isolated rabbit heart muscle, Arzneim Forsch./Drug
Res, 1992, 42(1), 111113
23.
Ozaki Y et al, Effects of oral hypoglycemic agents on platelet
function, Biochem Pharmacol. 1992, 44, 687691
24.
Groop L , Sulfonylureas in NIIDM, Diabetes Care, 1992, 15,
737754 Vegh A, Papp J G, Haemodynamic and other effects of
sulphonylurea drugs on the heart, Diab Res Clin Pract, 1996, 31,
Suppi, S43S53
|
|